V

Valkai

Agent platform for pharma and device workflows

Head of Security & Trust

Full-Time
$200k - $350k/yr+ Equity
Expert
San Francisco, CA, USA+1 moreMore locations: New York, NY, USA
Remote
CybersecuritySecurity Governance, Risk & Compliance

About the job

Requirements
  • Have built or scaled a security program and be able to work across strategy, technical investigation, and day-to-day execution.
  • Have personally led security reviews and customer audits, earned enterprise security teams' trust, and helped resolve deployment blockers.
  • Understand cloud architecture, identity and access, data flows, application security, and AI systems well enough to assess risk and work through solutions with engineers.
  • Have taken a company through audits or certifications, owning readiness, evidence, remediation, and ongoing program processes.
  • Prioritize meaningful risks, make practical tradeoffs, and determine which customer commitments the company can support.
  • Explain security and risk clearly to customers, engineers, and leadership, and create accountability across teams.
Responsibilities
  • Own the security strategy, roadmap, and operating program, with clear priorities, owners, and reporting on risk and progress.
  • Lead enterprise security reviews, technical diligence calls, questionnaires, and customer audits; partner with Sales and Legal on security requirements and contractual commitments.
  • Build and maintain the Trust Center, security documentation, architecture overviews, and reusable responses; automate evidence collection and review workflows to improve speed and accuracy.
  • Own the roadmap and execution for SOC 2, ISO 27001, and ISO 42001, including gap assessments, control implementation, auditor coordination, remediation, and ongoing maintenance.
  • Establish AI governance with Product, AI Research, Engineering, and Legal, including AI risk assessments, model and vendor reviews, data-handling practices, human oversight, and documented responsibilities.
  • Partner with Engineering to strengthen access controls, cloud and application security, tenant isolation, vulnerability management, and protections for AI agents and customer data.
  • Translate recurring customer concerns into product and security improvements, and select the tools, external partners, and future hires needed to scale the function.
Desired Qualifications
  • Have implemented an AI management system or led ISO 42001 certification.
  • Have supported life sciences organizations, financial institutions, law firms, or other highly regulated enterprise customers.
  • Have worked at an AI company or a high-growth enterprise software company.
  • Have experience with AI agent security, model-provider risk, privacy programs, or NIST AI RMF.
  • Have built security or compliance automation and be familiar with cloud environments such as AWS or Azure.
  • Hold relevant credentials such as CISSP, CISM, or ISO 27001/42001 Lead Implementer or Lead Auditor.

About the company

Valkai builds an agent orchestration layer for pharmaceutical, biotech, and medical device companies, connecting the siloed systems, teams, and outside data that make development slow. Its agents run on an organization's own SOPs, precedents, and regulatory context, draw on more than 100 data sources, and execute multi-step workflows that end in review-ready documents with citations, covering everything from discovery through commercialization. The company says more than 200 agent systems coordinate work across those stages, and it deploys through private cloud or managed SaaS. Unlike a general-purpose assistant, the agents are bound to the procedures and evidence standards a regulated submission requires. The company's goal is to compress work that currently takes months into weeks by removing the handoffs between systems.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie's September 29, 2026 deal creates a marquee reference for other pharma buyers.
  • Clinical data growth drives manual-review pain, increasing demand for Valkai's automation layer.
  • Valkai's compliance positioning around GDPR, SOC2, CLIA, and CAP lowers procurement friction.

What critics are saying

  • AbbVie is a single public proof point; losing it crushes credibility in 2026.
  • No disclosed pricing, rollout scope, or performance metrics leaves renewal risk unresolved.
  • Competitors like Microsoft, Google, and Insilico can bundle similar AI into existing stacks.

What makes Valkai unique

  • AbbVie partnered with Valkai on September 29, 2026, validating enterprise clinical-development demand.
  • Valkai targets life sciences workflows, combining data extraction, document preparation, and workflow automation.
  • Its team markets experience from OpenAI, Google DeepMind, Sierra, and Glean.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Vacation
  • Paid Parental Leave
  • Company Equity

Company News

Vialynx Inc
Sep 29th, 2026
AbbVie partners with Valkai to apply advanced AI across targeted areas of clinical development.

AbbVie partners with Valkai to apply advanced AI across targeted areas of clinical development. Science · SEP 29, 2026 PR Newswire AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across... * AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across clinical development * AbbVie is committed to integrating AI throughout the drug development journey to advance scientific innovation, strengthen operations and improve outcomes for patients NORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ - AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients. Through its partnership with Valkai, AbbVie will deploy purpose-built AI capabilities designed to improve efficiency across targeted areas of clinical research, help teams generate insights more quickly and support opportunities to reduce development timelines. AI plays an important role at AbbVie in advancing scientific innovation, strengthening connected operations and improving how medicines are discovered, developed and delivered to patients. Its partnership with Valkai builds on AbbVie's strong foundation of applying AI across R&D, helping to further scale data-driven insights and innovation. "At AbbVie, we are focused on applying AI where it can create meaningful impact for our business and, ultimately, for patients," said Nicholas Donoghoe, executive vice president, chief business and strategy officer, AbbVie. "As clinical data continues to grow in volume and complexity, partnerships like Valkai help us generate insights faster and enable our teams to spend more time on the decisions that matter most. By combining advanced AI capabilities with human expertise, we can help bring new medicines to patients more efficiently." Across AbbVie, AI serves as a critical tool to complement employee insight, enabling teams to drive strategic priorities and expedite delivery of medicines to patients, while maintaining a strong commitment to responsible and ethical use. "We're delighted to partner with AbbVie, combining advanced AI capabilities with deep scientific expertise," said Vignesh Rajendran, co-founder and chief executive officer, Valkai. "AbbVie's scale, innovation and unwavering focus on patients make this the kind of partnership that can turn bold ambition into meaningful impact." "For Clinical Sciences in particular, success depends on the ability to learn quickly, adapt intelligently and make confident decisions based on an ever-growing body of evidence," said Andrew Campbell, M.D., vice president, clinical sciences, AbbVie. "AI capabilities, like Valkai, have the potential to help us reduce time spent on manual processes and focus more attention on scientific interpretation and clinical strategy, and ultimately, the insights that can advance medicines for patients." About AI@AbbVie AI@AbbVie is AbbVie's enterprise approach to using artificial intelligence (AI) to advance scientific innovation, strengthen business outcomes and improve how medicines are discovered, developed and delivered to patients. AI is an important enabler of our mission, helping employees enhance productivity, strengthen decision-making and accelerate progress across R&D, operations and other core business functions. Guided by human expertise, responsible governance and a commitment to meaningful impact, we are embedding AI across the enterprise to accelerate innovation and help improve patients' lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. About Valkai Valkai is the AI operating system for life sciences. Its mission is to significantly accelerate time to market for the world's most critical medicines. Global Fortune 500 pharma and medtech leaders partner with Valkai to enable faster, smarter decision-making. The team hails from pioneering research and applied AI companies such as OpenAI, Google DeepMind, Sierra and Glean. AbbVie Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. | Media: Cat Langel (708) 508-3524 [email protected] | Investors: Liz Shea (847) 935-2211 [email protected] | SOURCE AbbVie Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.